Glucagon-like peptide-1 (GLP-1) receptor agonists, introduced in clinical practice in 2005, have revolutionized the treatment of type 2 diabetes, and their use represents a paradigm shift. GLP-1 receptor agonists have allowed for better control of glycemia when compared to basal insulin with minimal risk of hypoglycemia.1  The number of prescriptions for this medication class have risen sharply, with introduction of new pharmacologic agents and the wide adoption of GLP-1 receptor agonists for treatment of obesity. Clinicians frequently care for patients prescribed GLP-1 receptor agonists and need to be familiar with perioperative considerations. The anesthetic plan needs to be tailored based on the specific drug, the dosing schedule, fasting time, gastrointestinal symptoms, and the planned procedures. In this article, we discuss the pharmacokinetics of GLP-1 receptor agonists, mitigating factors affecting risks of aspiration, and risks and benefits of stopping or continuing GLP-1 receptor agonists perioperatively. We also propose a framework for periprocedural management of patients taking GLP-1 receptor agonists.

The clinical benefits of GLP-1 receptor agonists are derived partly through their propensity to slow down gastrointestinal motility. In the outpatient setting, reported gastrointestinal adverse events related to GLP-1 receptor agonists have risen as their utilization has surged.2  Most commonly reported side effects are abdominal pain (57.6%), nausea and vomiting (23.4%), constipation (30.4%), and diarrhea (32.7%).3  Gastrointestinal side effects occur for both short- and long-acting preparations, and for subcutaneously and orally administered preparations. Typically, these adverse effects are not serious, are self-limited, and are more pronounced at the initiation of the drug or during dose escalation phases. They often subside when maintenance doses are reached.

GLP-1 receptor agonists’ ability to slow gastric emptying to a gastroparesis level has translated into concerns for perioperative aspiration.4,5  Multiple case reports, case series, and studies have been published since 2022.6–21  These concerns led the American Society of Anesthesiologists (ASA; Schaumburg, Illinois) to publish a consensus-based guidance suggesting that patients discontinue GLP-1 receptor agonists for 1 day for short-acting preparations and 1 week for long-acting preparations, while observing the current ASA fasting guidelines without any modifications.22  However, the ASA recommendations have been questioned because of the lack of data supporting them and new data that are rapidly emerging.

There are several GLP-1 receptor agonists currently available (table 1). Short-acting preparations include lixisenatide and exenatide. The lixisenatide-alone formulation was withdrawn from the United States market in January 2023 but remains available in Europe. Lixisenatide is currently available only in combination with long-acting insulin in the United States. Exenatide is available as a short-acting twice-daily subcutaneous preparation or as a long-acting weekly formulation with the drug slowly released from a matrix. Other long-acting GLP-1 receptor agonists include liraglutide, dulaglutide, and semaglutide. Liraglutide is mostly albumin-bound, thus having a reservoir for prolonged release, which accounts for its long half-life.26  Dulaglutide is a GLP-1 molecule coupled with an immunoglobulin Fc fragment leading to slow degradation. Semaglutide is available in two forms: a weekly long-acting preparation, which is albumin-bound, and an oral form with low bioavailability after ingestion leading to the need for daily dosing.26 

Tirzepatide is a dual GLP-1 receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) dosed weekly and approved for treatment of diabetes mellitus and obesity. The various GLP-1 receptor agonists and their pharmacologic properties are presented in table 1. Orforglipron, a daily oral GLP-1 receptor agonist, and retatrutide, a triple GLP-1, GIP, and glucagon receptor agonist administered subcutaneously, are in late phases of development.27–29 

General principles guiding perioperative medication management include a thoughtful assessment of the risks and benefits of continuing or discontinuing a medication based on the indication, pharmacokinetics, and potential interactions with anesthetic agents. In certain circumstances, the planned procedure and the anesthetic are important considerations. Medications are withheld perioperatively in select circumstances when risks are perceived to outweigh benefits and no alternative measures can mitigate the periprocedural risks.

In patients with diabetes mellitus, GLP-1 receptor agonists reduce glycemia through multiple mechanisms such as slowing gastric emptying, increasing pancreatic insulin secretion, decreasing glucagon release, and decreasing appetite.30,31  In the outpatient setting, cardiovascular outcome trials and metanalyses demonstrate that GLP-1 receptor agonists reduce major adverse cardiovascular events, including acute myocardial infarction, stroke, and mortality in individuals with multiple cardiovascular risk factors and either type 2 diabetes or obesity.32–34  The American Diabetes Association (Arlington, Virginia) and the American Association of Clinical Endocrinology (Jacksonville, Florida) recommend GLP-1 receptor agonists as first-line drugs along with metformin for patients with type 2 diabetes with an established or high risk of atherosclerotic cardiovascular disease, stroke, transient ischemic attacks, or chronic kidney disease.35,36 

There are emerging data of the benefits of continuing GLP-1 receptor agonists during the perioperative period specifically in patients with diabetes mellitus.

  • Studies in cardiac surgery show glycemia benefit of GLP-1 receptor agonists (liraglutide and exenatide) when compared to insulin, and delayed initiation and lower doses of insulin needed for glycemic control37–42  (table 2).

  • Benefits of GLP-1 receptor agonist such as better glycemia control and fewer prosthetic joint infections have been described in patients having noncardiac surgeries. These effects are possibly explained by the immunomodulatory and anti-inflammatory effects of GLP-1 receptor agonists43,44  (table 2).

  • There is a lack of data on the benefits of continuing GLP-1 receptor agonists in patients with obesity, because all the studies to date have been performed in patients with diabetes mellitus.

The perioperative risks of continuing GLP-1 receptor agonists pertain to their propensity to delay gastric emptying, and concerns for perioperative aspiration of gastric contents. Self-reported symptomatology such as nausea and vomiting suggests delayed gastric emptying.45  However, lack of symptoms correlate poorly with gastric emptying. Data show that even when patients report no symptoms, they can still have significantly altered gastric emptying times.45  Evidence of delayed gastric emptying from GLP-1 receptor agonist comes from case reports and case series (table 3) and from outpatient gastric emptying studies (table 4).6–21,46–88 

A summary of studies and case reports of aspiration events and residual gastric contents assessed by ultrasonography or endoscopy is shown in table 3.

  • It is notable that in these reports, the patients followed current recommendations for fasting (i.e., 8 h fasting time for solids and 2 h for liquids).89 

  • Although the number of aspiration events is small, the vast majority occurred in patients receiving monitored anesthesia care. In a retrospective database review of patients having esophagogastroduodenoscopy, the only two aspiration events occurred in patients receiving monitored anesthesia care, and aspiration rates were comparable to those seen in the general population of patients receiving anesthesia.19 

  • The risk of aspiration does not appear to be increased in patients having emergency surgeries who have not had time to stop their GLP-1 receptor agonist, which may be partly due to the use of rapid sequence induction and intubation.20  Also, general endotracheal anesthesia seems to protect against the risk of aspiration.48 

While the risk of aspiration is present and should not be underappreciated, the evidence for delayed gastric emptying primarily comes from outpatient data. The data on gastric emptying in patients on GLP-1 receptor agonist are heterogeneous in nonprocedural and nonsurgical settings (table 4), and interpretation is nuanced.

  • These data are mixed with respect to the method used to assess gastric emptying; the studied population, which included patients with obesity, diabetes, or healthy volunteers; the reported results; and perioperative relevance.

  • The most accurate assessment of gastric emptying is the nuclear scintigraphic method, which evaluates solid food retention in the stomach. The gastric motility breath test is another infrequently used study to measure solid content transit times. However, few studies have assessed gastric emptying in patients taking GLP-1 receptor agonist using these methods. A recent metanalysis of studies looking at GLP-1 receptor agonist effects on gastric emptying reported prolonged times required for 50% of ingested gastric contents to leave the stomach. Patients taking GLP-1 receptor agonist had a time required for 50% of ingested gastric contents to leave the stomach of 138.4 min (95% CI, 74.5 to 202.3) versus 95.0 min (95% CI, 54.9 to 135.0) for the placebo group, with a pooled mean difference of 36.0 min (P < 0.01).88  This evidence supports a delayed gastric emptying of solid foods being decreased in patients taking GLP-1 receptor agonists.

  • The majority of studies have used an acetaminophen absorption test, which assesses gastric emptying of liquids rather than solids. Consequently, many experts consider data obtained from acetaminophen absorption studies inadequate to base clinical decisions ofor patients on GLP-1 receptor agonists.88  A metanalysis of 10 studies with 411 individuals using an acetaminophen test showed no significant delay in gastric emptying at 1, 4, and 5 h in patients taking GLP-1 receptor agonist.90  These data point toward normal emptying of liquids in these patients.

  • There is a difference between short- and long-acting drugs and their effects on gastric emptying. The plasma concentration of short-acting drugs peaks and decreases rapidly. This intermittent stimulation of the GLP-1 receptor may impact gastric emptying more than occurs with long-acting drugs, which continuously stimulate receptors, resulting in tachyphylaxis. It may take weeks to months for patients on short-acting medications to develop tachyphylaxis compared to 4 to 5 weeks for long-acting preparations.73 

  • Data on tachyphylaxis for long-acting preparations are mixed as well, with some studies showing that even long-acting preparations (liraglutide, weekly semaglutide, long-acting exenatide) significantly delay gastric emptying.62,65,67  These data are corroborated by a metanalysis reporting that the type of GLP-1 receptor agonist did not correlate with the gastric emptying effects regardless of the type of assessment (scintigraphy or acetaminophen absorption).90 

  • Gastric emptying studies have not assessed effects beyond 4 to 6 h. The limited evidence from emptying studies using scintigraphy have detected a prolongation (138 vs. 95 min) of gastric emptying measured at 4 h, which is much less than the recommended fasting time for solids, but longer than that recommended for liquids.

  • Gastric emptying effects are more pronounced in the first few weeks after initiating GLP-1 receptor agonists or escalating doses. During this time, gastric emptying for liquids can be prolonged as assessed by acetaminophen tests.13,87 

Overall, while the current gastric emptying studies may be difficult to interpret and extrapolate to the perioperative setting, the data point toward a prolonged gastric emptying time for solids. In addition, the presence of residual gastric contents directly observed via endoscopy in patients fasting for solids between 8 and 18 h provides irrefutable evidence that gastric emptying time for solids is affected, regardless of the duration of therapy or patients being in a maintenance phase.12,21  While effects on gastric emptying for solids are more pronounced with short-acting preparations and long-acting GLP-1 receptor agonists during therapy initiation or dose escalation, some studies show delays in gastric emptying even during the maintenance phase. Emptying time for liquids may not be as significantly impacted with long-acting preparations during steady state due to tachyphylaxis. However, liquid emptying remains slightly prolonged with short-acting preparations, and during start of therapy or dose escalation periods with long-acting GLP-1 receptor agonists.13,86 

The potential benefit of stopping GLP-1 receptor agonists for only one pharmacologic half-life has come under scrutiny. There are several considerations that counter the benefit of stopping the GLP-1 receptor agonist, including the following:

  • Pharmacokinetic data demonstrate that there is residual circulating drug after missing one dose of both short- and long-acting GLP-1 receptor agonists.

    • Pharmacokinetic modeling of liraglutide shows that at the end of one half-life of elimination, the blood concentration is higher in patients taking 1.8 mg compared to the peak concentration of liraglutide 0.6 mg24  (fig. 1).

    • The simulated semaglutide concentration dosed at 1 mg showed that when missing one dose, there was a 48% decrease in minimum concentration expected before the next planned dose 7 days later. Delaying the dose 5 days causes minimum semaglutide concentrations to be 37% lower and the maximum concentration after the next dose to be 14% higher compared with the same subject at a normal weekly steady state. In both cases, the nadir of the semaglutide concentrations is higher than the mean concentration at steady state of a similar patient taking 0.5 mg weekly, and closer to regular steady state after 3 weeks91  (fig. 2).

    • Similarly, if a dose of dulaglutide or tirzepatide is missed, there is residual circulating GLP-1 receptor agonist. Moreover, if a dose of dulaglutide is not taken within 3 days or if tirzepatide is held for 4 days, there are transient 20% higher concentrations after the subsequent doses of the GLP-1 receptor agonist25,92  (figs. 3 and 4).

    • Package inserts advise skipping the missed dose and administering the GLP-1 receptor agonist on the regularly scheduled day if fewer than 3 days remain until the next dose for exenatide, dulaglutide, or tirzepatide, or fewer than 2 days for semaglutide.93 

  • More importantly, clinical data confirm that even when a GLP-1 receptor agonist dose is omitted, some patients have residual gastric contents on the day of procedure while following standard fasting guidelines.89 

    • A prospective study of 124 patients presenting for surgeries found ultrasonographic confirmation of increased gastric contents defined by the presence of solids, thick liquids, or more than 1.5 ml/kg clear liquids in patients taking GLP-1 receptor agonists. Interestingly, there was no association between the duration of drug interruption and the prevalence of increased gastric contents, including in some patients who had stopped their drugs more than 7 days before surgery.21 

    • Another study of 404 patients found no relationship between the interval interruption of semaglutide and the presence of residual gastric contents in patients having endoscopies. The interruption intervals of semaglutide in patients without retained gastric contents were 10 days (6 to 15) compared to 11 days (7.75 to 12.5) in those with delayed emptying (P = 0.67).12 

Considerations of risks associated with stopping GLP-1 receptor agonists are the following:

  • In patients with diabetes mellitus prescribed GLP-1 receptor agonists, no glycemic data are available on the effects of stopping GLP-1 receptor agonists. It is likely that glycemia control will deteriorate, especially in those with poor control, requiring multidrug regimens, taking insulin, or on high doses of antihyperglycemics. Moreover, acute hyperglycemia slows gastric emptying, so it is possible that this will negate the benefit of stopping the drugs.94 

  • Patients taking high doses of GLP-1 receptor agonists (more common in obese patients, but also in patients with diabetes) and those experiencing severe symptoms at initiation or during escalation of treatment are at high risk of adverse gastrointestinal effects when doses are missed and then restarted.93  These patients often need to be started on a lower dose of drug to mitigate side effects. However, this is logistically difficult since some of these medications (e.g., tirzepatide, dulaglutide) are packaged in prefilled syringes, and patients are provided with precise doses monthly. In contrast, semaglutide pens allow adjustment of doses.93 

Both pharmacokinetic and clinical data indicate that short interruptions of long-acting GLP-1 receptor agonist (i.e., one half-life) are not sufficient to ensure complete clearance of the drug. While no data are available on gastric emptying from residual GLP-1 receptor agonist concentrations, it is likely that there is no complete dissipation of the effect. The longer duration of interruption needed (i.e., 4 or 5 half-lives) is impractical, potentially harmful, and not patient-centric.

Moreover, there are data suggesting safety of continuation of GLP-1 receptor agonists periprocedurally. A study in patients having endoscopy while continuing their medications and following a modified fasting regimen reported no increased gastric volumes and no aspiration events.53 

Symptomatic patients describing severe gastrointestinal symptoms may represent a special category where the medication regimen can be interrupted or dose de-escalated. However, even in these patients, current guidelines recommend dietary interventions such as small frequent meals and consumption of bland foods as a first-line intervention.95,96  Medication adjustments are recommended only when symptoms do not resolve.95,96 

Current guidance suggests that the standard fasting time is sufficient to mitigate aspiration risk in patients taking GLP-1 receptor agonists.22  However, this approach is questionable based on clinical data (table 3).

Considerations for solid fasting times are the following:

  • Many patients found to have residual gastric contents on the day of their procedures have observed the standard ASA fasting times.12,21  In these studies, despite interrupting GLP-1 receptor agonist for more than 7 days, patients had retained gastric contents.12,21 

  • Data from a case control study showed lower rates of persistent stomach contents in patients having afternoon procedures with prolonged fasting compared to those having procedures in the morning (4% vs. 11%; P < 0.01).17 

  • Several studies reveal that patients having colonoscopies (with or without upper endoscopies) have a lower incidence of retained gastric contents.12,16,17,47  This is most likely due to the fact that patients having colonoscopies typically follow a clear liquid diet the day before the procedure, and less likely due to the concurrent bowel preparation.97 

The evidence suggests that an extended fasting time for solids should be recommended for patients taking GLP-1 receptor agonists. Perhaps the best data in support of this approach come from a study of 57 patients having endoscopies where GLP-1 receptor agonists were not stopped. All of the patients followed a liquid diet for 24 h or more and were nil per os (nothing by mouth; NPO) for more than 12 h before their endoscopies. No patients had detectable residual gastric contents determined by endoscopy, and no aspiration events occurred.53  Overall, there is clear evidence of delayed gastric emptying for solids irrespective of the type of GLP 1 receptor agonist preparation or duration of treatment, suggesting that a clear liquid diet for 24 h or more may be necessary for these patients.

At this time, the best duration of fasting from liquids is unclear because data are scarce and heterogeneous.

  • Various liquids empty from the stomach at different rates. High-caloric liquids (those containing fat or greater than 10% glucose) empty more slowly than water or low caloric clear liquids (10% glucose or less) in patients with normal gastric emptying.98 

  • Patients on short-acting preparations have delayed gastric emptying for liquids after weeks of treatments. Significant liquid intragastric content has been described at 4 h after 8 weeks of treatment with lixisenatide with consumption of high-caloric glucose–containing liquids.73–76 

  • In individual studies, patients on long-acting preparations in a maintenance phase at least 4 weeks from initiation seem to have slightly prolonged delays in gastric emptying for liquids in the first 1 to 2 h that normalize by 5 h.84–86  However, in the majority of these studies, acetaminophen elixir was given after a solid meal, which likely confounds the data and may overestimate the delay (table 4).

  • Patients who recently started or dose-escalated long-acting GLP-1 receptor agonist within the previous 4 weeks do not exhibit tachyphylaxis and may need more prolonged NPO fasting times. A study of 20 patients detected that 30% of the semaglutide group (most of whom had been on therapy for less than 4 weeks) compared to 90% of the controls were considered to have empty stomachs 2 h after drinking 12 oz of clear liquids in a supine position.13  These findings corroborate other data on gastric emptying assessed by acetaminophen absorption.87 

  • A recently published meta-analysis did not show any significant delay in gastric emptying for liquids regardless of the GLP-1 receptor agonist. However, it did not include all of the studies, and there was heterogenicity in the reported measurements and in the nature of the meals coadministered with the acetaminophen.90 

There are concerns that prolonged fasting for liquids is not patient friendly and counters the principles of enhanced recovery. High-caloric carbohydrate drinks have been shown to empty slower than water even in patients not taking GLP-1 receptor agonists. They are generally not recommended in patients with diabetes where the risks of hyperglycemia may outweigh their benefits.99  They may be restricted for longer than 4 h in patients on GLP-1 receptor agonists for obesity, because their emptying is particularly delayed, especially by short-acting GLP-1 receptor agonist.73–76 

Extended restriction periods for other non- or low-caloric clear liquids may not be advantageous or necessary for the majority of patients on maintenance doses of long-acting GLP-1 receptor agonists for more than 4 weeks. However, not all patients exhibit tachyphylaxis.61  The evidence suggests fasting for non- or low-caloric clear liquids for longer than current recommendations is necessary for patients taking long-acting preparations during initiation and dose escalation periods, and those on short-acting GLP-1 receptor agonists.

Point-of-care gastric ultrasonography has been used to identify patients taking GLP-1 receptor agonists who have residual gastric content preprocedurally.10,13,21,51,99,100 101  Training and achieving proficiency in gastric ultrasonography followed by wide adoption among anesthesiology clinicians will take some time. Most importantly, gastric ultrasonography only identifies those with retained gastric contents after they arrive for their procedures. It does not allow for timely interventions to avoid the risk of perioperative aspiration other than a change in the planned anesthetic or postponement of the procedure. A better approach is needed to ensure a majority of patients taking GLP-1 receptor agonists present without retained gastric contents preprocedurally and can avoid unnecessary anesthesia procedures such as rapid sequence induction and intubation, or aspiration on emergence from anesthesia. Gastric ultrasonography may be best suited for patients who are symptomatic or are asymptomatic without having observed prolonged fasting times.

Emerging data point to the limitations of the current ASA consensus-based guidance for patients taking GLP-1 receptor agonists. It is becoming more obvious that interrupting GLP-1 receptor agonists as currently suggested may not offer much benefit, since a longer washout time is needed to resolve the effects on gastric emptying. Moreover, the current approach gives clinicians a false sense of security when proceeding with anesthesia, especially when a monitored anesthesia care or a standard general anesthesia induction technique is planned, as residual gastric contents may be present. Furthermore, the glycemia benefit and the perioperative effects of mitigating major adverse cardiovascular events may be lost with drug interruptions in patients with diabetes mellitus. Additionally, there is the possibility of renewed side effects when reinstating a high-dose GLP-1 receptor agonist, and de-escalating may not be feasible due to fixed-dose prefilled pen preparations.

GLP-1 receptor agonists may need to be interrupted in patients who have recently started these medications or are in dose escalation phases, and have significant symptoms of fullness, nausea, and vomiting. Stopping the drugs or de-escalating doses, when possible, may be beneficial to decrease risks of aspiration in these patients who have not reached a steady state or developed tachyphylaxis to the gastrointestinal side effects. These patients may be referred to their prescribing physician for diet and medication modification before proceeding with elective procedures requiring anesthesia.

However, the first and most important intervention appears to be changing the duration of fasting for solids and possibly for liquids. Prolonged fasting time for solid foods beyond current recommendations is likely more effective than drug interruption to prevent patients from presenting on the day of procedures with residual gastric contents.53  Data from the “real world” and gastric emptying studies support recommending a clear liquid diet for 24 h before anesthesia.53  The fasting duration for liquids is unclear at this time, but it appears that patients who have recently started a long-acting GLP-1 receptor agonist or are in the dose escalation period and those on short-acting preparations may need a more prolonged NPO time than currently recommended. The caloric content of the liquids is important, with high-caloric clear liquids likely needing a longer fasting time than the low- or noncaloric clear liquids (8 h vs. 4 h). While these timeframes for liquids may appear arbitrary, data suggest that complete NPO times ranging between 4 and 12 h are more likely to result in lower gastric volumes, thus balancing the risks of aspiration with enhanced recovery principles.

Patients not tolerating the GLP-1 receptor agonist should be advised to follow a bland, low-fat, and low-fiber diet and to eat small meals. Medication changes (i.e., dose de-escalation) are secondarily considered. Elective surgeries should be postponed in patients with significant symptoms refractory to these interventions. Patients who are planning dose escalation should be advised not to do so in the weeks leading up to elective procedures. Collaboration with the prescribing clinicians is important when making decisions.

Proceeding with the planned anesthetic appears safe for asymptomatic patients presenting for elective procedures who are in maintenance phases, and have followed clear liquid diets for 24 h. For symptomatic patients orthose who have not been on clear liquids for 24 h, a gastric ultrasound may help guide decisions.

Since the publication of the ASA consensus-based guidance, a number of studies have been published on the gastric emptying effects of GLP-1 receptor agonists. Therefore, we propose updated recommendations for decision-making during the preoperative period and on the day of surgery (figs. 5 and 6).

Conclusions

Data on the perioperative management of patients taking GLP-1 receptor agonists are sparse, but emerging. There is heterogenicity as to the subjects studied (healthy controls, patients with obesity or diabetes) and the tests and measurements used, which may limit the ability to extrapolate findings across populations. Perioperative clinicians need to consider indications for medication, dosing schedule, concurrent symptoms, and the logistics of access to the medications in specific doses. Dietary recommendations, anesthetic options, and the relative urgency of the proposed procedure are also important factors to review. Indeed, a multidisciplinary, patient-centric approach is needed when caring for these patients.

Acknowledgments

The authors of this article served on the Society for Perioperative Assessment and Quality Improvement (SPAQI; Boston, Massachussetts) taskforce on GLP-1 RAs, with Dr. Oprea in the role of Chair. There was timing overlap between the work of the SPAQI taskforce and the last revision of the manuscript, and the authors acknowledge the taskforce for the discussion on liquid fasting times. The authors also want to acknowledge the ongoing work of the SPAQI taskforce that may result in future publication of recommendations for patients on GLP-1 RAs. Finally, the authors would like to acknowledge Michael Camilleri, M.D., D.Sc., Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, for his contribution to their understanding of the gastric emptying studies.

Research Support

Support was provided solely from institutional and/or departmental sources.

Competing Interests

Dr. Oprea reports honoraria from Westchester Medical Center (Valhalla, New York) and Brigham and Women’s Hospital (Boston, Massachusetts). Dr. Umpierrez received grant support from Novo Nordisk (Bagsværd, Denmark), Merck (Rahway, New Jersey), Insulcloud (Madrid, Spain), Dexcom (San Diego, California), Abbott (Green Oaks, Illinois), AstraZeneca (Cambridge, United Kingdom), and Bayer (Leverkusen, Germany). Dr. Sweitzer received funding from UpToDate (Boston, Massachussetts), International Anesthesia Research Society (San Francisco, California), and Medtronic (Minneapolis, Minnesota). Dr. Hepner received funding from Pharmacosmos (Holbæk, Denmark) and UpToDate.

1.
Nauck
MA
,
Mirna
AEA
,
Quast
DR
:
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Diabetes Obes Metab
2023
;
25
:
1361
71
2.
Liu
L
,
Chen
J
,
Wang
L
,
Chen
C
,
Chen
L
:
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Front Endocrinol (Lausanne)
2022
;
13
:
1043789
3.
Aldhaleei
WA
,
Abegaz
TM
,
Bhagavathula
AS
:
Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: A cross-sectional analysis of the National Institutes of Health All of Us Cohort.
Pharmaceuticals (Basel)
2024
;
17
:
199
4.
Kalas
MA
,
Galura
GM
,
McCallum
RW
:
Medication-induced gastroparesis: A case report.
J Investig Med High Impact Case Rep
2021
;
9
:
23247096211051919
5.
Almustanyir
S
,
Alhabeeb
H
,
AlHusseini
N
,
Al Thow
M
:
Gastroparesis with the initiation of liraglutide: A case report.
Cureus
2020
;
12
:
e11735
6.
Gulak
MA
,
Murphy
P
:
Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: A case report.
Can J Anaesth
2023
;
70
:
1397
400
7.
Klein
SR
,
Hobai
IA
:
Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: A case report.
Can J Anaesth
2023
;
70
:
1394
6
8.
Fujino
E
,
Cobb
KW
,
Schoenherr
J
,
Gouker
L
,
Lund
E
:
Anesthesia considerations for a patient on semaglutide and delayed gastric emptying.
Cureus
2023
;
15
:
e42153
9.
Avraham
SA
,
Hossein
J
,
Somri
F
,
Hawash
N
,
Hochman
O
:
Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss.
Anaesth Rep
2024
;
12
:
e12278
10.
Kittner
SL
,
Talbott
AL
,
Vishneski
SR
,
Narbaiza
J
,
Shields
JS
:
Retained gastric contents after adequate fasting associated with GLP-1 receptor agonist use: A report of 3 cases.
JBJS Case Connect
2023
;
13
:
e23.00506
11.
Stark
JE
,
Cole
JL
,
Ghazarian
RN
,
Klass
MJ
:
Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD).
Ann Pharmacother
2022
;
56
:
922
6
12.
Silveira
SQ
,
da Silva
LM
,
de Campos Vieira Abib
A
et al
:
Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.
J Clin Anesth
2023
;
87
:
111091
13.
Sherwin
M
,
Hamburger
J
,
Katz
D
,
DeMaria
S
:
Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: A prospective observational study in volunteers without obesity recently started on semaglutide.
Can J Anaesth
2023
;
70
:
1300
6
14.
Kobori
T
,
Onishi
Y
,
Yoshida
Y
et al
:
Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.
J Diabetes Investig
2023
;
14
:
767
73
15.
Nadeem
D
,
Taye
M
,
Still
MD
et al
:
Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and non-diabetic patients.
Gastrointest Endosc
2024
:
S0016
5107(24)03159
[Epub ahead of print]
16.
Firkins
SA
,
Yates
J
,
Shukla
N
,
Garg
R
,
Vargo
JJ
,
Lembo
A
;
Cleveland Clinic Obesity Medicine and Bariatric Endoscopy Working Group
:
Clinical outcomes and safety of upper endoscopy while on glucagon-like peptide-1 receptor agonists.
Clin Gastroenterol Hepatol
2024
:
S1542
3565(24)00295
[Epub ahead of print]
17.
Garza
K
,
Aminpour
E
,
Shah
J
et al
:
Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: A case-control study.
Am J Gastroenterol
2024
;
119
:
1081
8
18.
Wu
F
,
Smith
MR
,
Mueller
AL
et al
:
Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: A historical cohort study.
Can J Anaesth
2024
;
71
:
958
66
19.
Anazco
D
,
Fansa
S
,
Hurtado
MD
,
Camilleri
M
,
Acosta
A
:
Low incidence of pulmonary aspiration during upper endoscopy in patients prescribed a glucagon-like peptide 1 receptor agonist.
Clin Gastroenterol Hepatol
2024
;
22
:
1333
5.e2
20.
Dixit
AA
,
Bateman
BT
,
Hawn
MT
,
Odden
MC
,
Sun
EC
:
Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications.
JAMA
2024
;
331
:
1672
3
21.
Sen
S
,
Potnuru
PP
,
Hernandez
N
et al
:
Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia.
JAMA Surg
2024
;
159
:
660
7
22.
Joshi
GP
,
Abdelmalak
BB
,
Weigel
WA
et al
:
American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists.
23.
Knop
FK
,
Brønden
A
,
Vilsbøll
T
:
Exenatide: Pharmacokinetics, clinical use, and future directions.
Expert Opin Pharmacother
2017
;
18
:
555
71
24.
Jacobsen
LV
,
Flint
A
,
Olsen
AK
,
Ingwersen
SH
:
Liraglutide in type 2 diabetes mellitus: Clinical pharmacokinetics and pharmacodynamics.
Clin Pharmacokinet
2016
;
55
:
657
72
25.
Geiser
JS
,
Heathman
MA
,
Cui
X
et al
:
Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: Analyses of data from clinical trials.
Clin Pharmacokinet
2016
;
55
:
625
34
26.
Nauck
MA
,
Quast
DR
,
Wefers
J
,
Meier
JJ
:
GLP-1 receptor agonists in the treatment of type 2 diabetes - State-of-the-art.
Mol Metab
2021
;
46
:
101102
27.
Rosenstock
J
,
Frias
J
,
Jastreboff
AM
et al
:
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet
2023
;
402
:
529
44
28.
Wharton
S
,
Blevins
T
,
Connery
L
et al
;
GZGI Investigators
:
Daily oral GLP-1 receptor agonist orforglipron for adults with obesity.
N Engl J Med
2023
;
389
:
877
88
29.
Jastreboff
AM
,
Kaplan
LM
,
Frías
JP
et al
;
Retatrutide Phase 2 Obesity Trial Investigators
:
Triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial.
N Engl J Med
2023
;
389
:
514
26
30.
Lee
YS
,
Jun
HS
:
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Metabolism
2014
;
63
:
9
19
31.
Nauck
MA
,
Meier
JJ
:
Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Eur J Endocrinol
2019
;
181
:
R211
34
32.
Zhao
X
,
Wang
M
,
Wen
Z
et al
:
GLP-1 receptor agonists: Beyond their pancreatic Effects.
Front Endocrinol (Lausanne)
2021
;
12
:
721135
33.
Stefanou
MI
,
Theodorou
A
,
Malhotra
K
et al
:
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.
Eur Stroke J
2024
;
9
:
530
9
34.
Singh
S
,
Garg
A
,
Tantry
US
,
Bliden
K
,
Gurbel
PA
,
Gulati
M
:
Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.
Curr Probl Cardiol
2024
;
49
:
102403
35.
American Diabetes Association Professional Practice Committee
:
9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024.
Diabetes Care
2024
;
47
:
S158
78
36.
Samson
SL
,
Vellanki
P
,
Blonde
L
et al
:
American Association of Clinical Endocrinology consensus statement: Comprehensive type 2 diabetes management algorithm - 2023 Update.
Endocr Pract
2023
;
29
:
305
40
37.
Polderman
JAW
,
van Steen
SCJ
,
Thiel
BG
et al
:
Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: A randomised controlled trial.
Anaesthesia
2018
;
73
:
332
9
38.
Hulst
AH
,
Visscher
MJ
,
Godfried
MB
et al
;
GLOBE Study Group
:
Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: A multicentre randomized superiority trial.
Diabetes Obes Metab
2020
;
22
:
557
65
39.
Makino
H
,
Tanaka
A
,
Asakura
K
et al
:
Addition of low-dose liraglutide to insulin therapy is useful for glycaemic control during the peri-operative period: Effect of glucagon-like peptide-1 receptor agonist therapy on glycaemic control in patients undergoing cardiac surgery (GLOLIA study).
Diabet Med
2019
;
36
:
1621
8
40.
Lipš
M
,
Mráz
M
,
Kloučková
J
et al
:
Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.
Diabetes Obes Metab
2017
;
19
:
1818
22
41.
Besch
G
,
Perrotti
A
,
Mauny
F
et al
:
Clinical effectiveness of intravenous exenatide infusion in perioperative glycemic control after coronary artery bypass graft surgery: A phase II/III randomized trial.
Anesthesiology
2017
;
127
:
775
87
42.
Watkins
AR
,
Fialka
N
,
El-Andari
R
,
Kang
JJ
,
Bozso
SJ
,
Nagendran
J
:
Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: A systematic review and meta-analysis of randomized control trials.
Future Cardiol
2023
;
19
:
105
15
43.
Kaneko
S
,
Ueda
Y
,
Tahara
Y
:
GLP1 receptor agonist liraglutide is an effective therapeutic option for perioperative glycemic control in type 2 diabetes within Enhanced Recovery After Surgery (ERAS) protocols.
Eur Surg Res
2018
;
59
:
349
60
44.
Magruder
ML
,
Miskiewicz
MJ
,
Rodriguez
AN
,
Mont
MA
:
Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions.
J Arthroplasty
2024
;
39
:
716
20
45.
Jalleh
RJ
,
Jones
KL
,
Rayner
CK
,
Marathe
CS
,
Wu
T
,
Horowitz
M
:
Normal and disordered gastric emptying in diabetes: Recent insights into (patho)physiology, management and impact on glycaemic control.
Diabetologia
2022
;
65
:
1981
93
46.
Weber
M
,
Siddarthan
I
,
Mack
PF
:
Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss.
Br J Anaesth
2023
;
131
:
e37
9
47.
Yeo
YH
,
Gaddam
S
,
Ng
WH
,
Huang
P-C
,
Ma
KS
,
Rezaie
A
;
Motility and Metabolic Pharmacoepidemiology Group
:
Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use.
Gastroenterology
2024
;
167
:
402
4.e3
48.
Klonoff
DC
,
Kim
SH
,
Galindo
RJ
et al
:
Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.
Diabetes Obes Metab
2024
;
26
:
3128
36
.
49.
Barlowe
TS
,
Anderson
C
,
Sandler
RS
et al
:
Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes.
Clin Gastroenterol Hepatol
2024
:
S1542
3565(24)00453
[Epub ahead of print]
50.
Queiroz
VNF
,
Falsarella
PM
,
Chaves
RCF
,
Takaoka
F
,
Socolowski
LR
,
Garcia
RG
:
Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: A case report with tomographic evidence.
Einstein (Sao Paulo)
2023
;
21
:
eRC0628
51.
Hodgson
JA
,
Rivera-Rodriguez
H
,
Wu
P
,
Udani
J
,
Weiss
J
:
Point-of-care ultrasound aids in the management of patient taking semaglutide before surgery: A case report.
A A Pract
2024
;
18
:
e01762
52.
Chapman
MB
,
Norwood
DA
,
Price
C
et al
:
Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during esophagogastroduodenoscopy.
Gastrointest Endosc
2024
:
S0016
5107(24)03208
[Epub ahead of print]
53.
Maselli
DB
,
Lee
D
,
Bi
D
et al
:
Safe continuation of glucagon-like peptide 1 receptor agonists at endoscopy: A case series of 57 adults undergoing endoscopic sleeve gastroplasty.
Obes Surg
2024
;
34
:
2369
74
54.
Acosta
A
,
Camilleri
M
,
Burton
D
et al
:
Exenatide in obesity with accelerated gastric emptying: A randomized, pharmacodynamics study.
Physiol Rep
2015
;
3
:
e12610
55.
Linnebjerg
H
,
Park
S
,
Kothare
PA
et al
:
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Regul Pept
2008
;
151
:
123
9
56.
Kuwata
H
,
Yabe
D
,
Murotani
K
et al
:
Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
J Diabetes Investig
2021
;
12
:
2162
71
57.
Quast
DR
,
Schenker
N
,
Menge
BA
,
Nauck
MA
,
Kapitza
C
,
Meier
JJ
:
Effects of lixisenatide versus liraglutide (short- and long-acting GLP-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes.
Diabetes Care
2020
;
43
:
2137
45
58.
Lorenz
M
,
Pfeiffer
C
,
Steinsträsser
A
et al
:
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes–Relationship to postprandial glycemia.
Regul Pept
2013
;
185
:
1
8
59.
Meier
JJ
,
Menge
BA
,
Schenker
N
et al
:
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
Diabetes Obes Metab
2020
;
22
:
599
611
60.
Meier
JJ
,
Rosenstock
J
,
Hincelin-Méry
A
et al
:
Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial.
Diabetes Care
2015
;
38
:
1263
73
61.
Jones
KL
,
Huynh
LQ
,
Hatzinikolas
S
et al
:
Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.
Diabetes Obes Metab
2020
;
22
:
788
97
62.
Maselli
D
,
Atieh
J
,
Clark
MM
et al
:
Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.
Obesity (Silver Spring)
2022
;
30
:
1608
20
63.
Nagai
Y
,
Hashimoto
E
,
Oikawa
R
et al
:
Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes.
Diabetes Obes Metab
2014
;
16
:
573
6
64.
Halawi
H
,
Khemani
D
,
Eckert
D
et al
:
Effects of liraglutide on weight, satiation, and gastric functions in obesity: A randomised, placebo-controlled pilot trial.
Lancet Gastroenterol Hepatol
2017
;
2
:
890
9
65.
Nakatani
Y
,
Maeda
M
,
Matsumura
M
et al
:
Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.
Diabetes Metab
2017
;
43
:
430
7
66.
Jensterle
M
,
Ferjan
S
,
Ležaič
L
et al
:
Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.
Diabetes Obes Metab
2023
;
25
:
975
84
67.
Cervera
A
,
Wajcberg
E
,
Sriwijitkamol
A
et al
:
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Am J Physiol Endocrinol Metab
2008
;
294
:
E846
52
68.
DeFronzo
RA
,
Okerson
T
,
Viswanathan
P
,
Guan
X
,
Holcombe
JH
,
MacConell
L
:
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study.
Curr Med Res Opin
2008
;
24
:
2943
52
69.
Drucker
DJ
,
Buse
JB
,
Taylor
K
et al
;
DURATION-1 Study Group
:
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study.
Lancet
2008
;
372
:
1240
50
70.
Kolterman
OG
,
Kim
DD
,
Shen
L
et al
:
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Am J Health Syst Pharm
2005
;
62
:
173
81
71.
Juel
CTB
,
Lund
A
,
Andersen
MM
et al
:
The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: A randomised, placebo-controlled, double-blinded crossover trial.
Diabetologia
2020
;
63
:
1285
98
72.
Becker
RH
,
Stechl
J
,
Steinstraesser
A
,
Golor
G
,
Pellissier
F
:
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
Diabetes Metab Res Rev
2015
;
31
:
610
8
73.
Jones
KL
,
Rigda
RS
,
Buttfield
MDM
et al
:
Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.
Diabetes Obes Metab
2019
;
21
:
1158
67
74.
Jalleh
R
,
Pham
H
,
Marathe
CS
et al
:
Acute effects of lixisenatide on energy intake in healthy subjects and patients with type 2 diabetes: Relationship to gastric emptying and intragastric distribution.
Nutrients
2020
;
12
:
1962
75.
Rayner
CK
,
Watson
LE
,
Phillips
LK
et al
:
Effects of sustained treatment with lixisenatide on gastric emptying and postprandial glucose metabolism in type 2 diabetes: A randomized controlled trial.
Diabetes Care
2020
;
43
:
1813
21
76.
Kovoor
JG
,
Rayner
CK
,
Wu
T
et al
:
Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures.
J Diabetes Complications
2024
;
38
:
108793
77.
Barrington
P
,
Chien
JY
,
Showalter
HD
et al
:
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
Diabetes Obes Metab
2011
;
13
:
426
33
78.
Degn
KB
,
Juhl
CB
,
Sturis
J
et al
:
One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Diabetes
2004
;
53
:
1187
94
79.
Dejgaard
TF
,
Frandsen
CS
,
Hansen
TS
et al
:
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): A randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol
2016
;
4
:
221
32
80.
Flint
A
,
Kapitza
C
,
Hindsberger
C
,
Zdravkovic
M
:
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Adv Ther
2011
;
28
:
213
26
81.
Horowitz
M
,
Flint
A
,
Jones
KL
et al
:
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Diabetes Res Clin Pract
2012
;
97
:
258
66
82.
van Can
J
,
Sloth
B
,
Jensen
CB
,
Flint
A
,
Blaak
EE
,
Saris
WH
:
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
Int J Obes (Lond)
2014
;
38
:
784
93
83.
Saxena
AR
,
Banerjee
A
,
Corbin
KD
,
Parsons
SA
,
Smith
SR
:
Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial.
Obes Sci Pract
2021
;
7
:
281
90
84.
Hjerpsted
JB
,
Flint
A
,
Brooks
A
,
Axelsen
MB
,
Kvist
T
,
Blundell
J
:
Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.
Diabetes Obes Metab
2018
;
20
:
610
9
85.
Dahl
K
,
Brooks
A
,
Almazedi
F
,
Hoff
ST
,
Boschini
C
,
Baekdal
TA
:
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
Diabetes Obes Metab
2021
;
23
:
1594
603
86.
Friedrichsen
M
,
Breitschaft
A
,
Tadayon
S
,
Wizert
A
,
Skovgaard
D
:
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Diabetes Obes Metab
2021
;
23
:
754
62
87.
Urva
S
,
Coskun
T
,
Loghin
C
et al
:
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Diabetes Obes Metab
2020
;
22
:
1886
91
88.
Maselli
DB
,
Camilleri
M
:
Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity.
Adv Exp Med Biol
2021
;
1307
:
171
92
89.
Joshi
GP
,
Abdelmalak
BB
,
Weigel
WA
et al
:
2023 American Society of Anesthesiologists practice guidelines for preoperative fasting: Carbohydrate-containing clear liquids with or without protein, chewing gum, and pediatric fasting duration-A modular update of the 2017 American Society of Anesthesiologists Practice Guidelines for Preoperative Fasting.
Anesthesiology
2023
;
138
:
132
51
90.
Hiramoto
B
,
McCarty
TR
,
Lodhia
NA
et al
:
Quantified metrics of gastric emptying delay by GLP-1 agonists: A systematic review and meta-analysis with insights for periprocedural management.
Am J Gastroenterol
2024
;
119
:
1126
40
91.
Carlsson Petri
KC
,
Ingwersen
SH
,
Flint
A
,
Zacho
J
,
Overgaard
RV
:
Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis.
Diabetes Ther
2018
;
9
:
1533
47
92.
Schneck
K
,
Urva
S
:
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
CPT Pharmacometrics Syst Pharmacol
2024
;
13
:
494
503
93.
Whitley
HP
,
Trujillo
JM
,
Neumiller
JJ
:
Special report: Potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages.
Clin Diabetes
2023
;
41
:
467
73
94.
Arunachala Murthy
T
,
Chapman
M
,
Jones
KL
,
Horowitz
M
,
Marathe
CS
:
Inter-relationships between gastric emptying and glycaemia: Implications for clinical practice.
World J Diabetes
2023
;
14
:
447
59
95.
Gorgojo-Martínez
JJ
,
Mezquita-Raya
P
,
Carretero-Gómez
J
et al
:
Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: A multidisciplinary expert consensus.
J Clin Med
2022
;
12
:
145
96.
Wharton
S
,
Davies
M
,
Dicker
D
et al
:
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice.
Postgrad Med
2022
;
134
:
14
9
97.
Yao
R
,
Gala
KS
,
Ghusn
W
,
Abboud
DM
,
Wallace
FK
,
Vargas
EJ
:
Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy.
Am J Gastroenterol
2024
;
119
:
1154
7
98.
Rüggeberg
A
,
Meybohm
P
,
Nickel
EA
:
Preoperative fasting and the risk of pulmonary aspiration-a narrative review of historical concepts, physiological effects, and new perspectives.
BJA Open
2024
;
10
:
100282
99.
Korytkowski
MT
,
Muniyappa
R
,
Antinori-Lent
K
et al
:
Management of hyperglycemia in hospitalized adult patients in non-critical care settings: An Endocrine Society clinical practice guideline.
J Clin Endocrinol Metab
2022
;
107
:
2101
28
100.
Girón-Arango
L
,
Perlas
A
:
Point-of-care gastric ultrasound to identify a full stomach on a diabetic patient taking a glucagon-like peptide 1 receptor agonist.
A A Pract
2024
;
18
:
e01751
101.
Willson
CM
,
Patel
L
,
Middleton
P
,
Desai
M
:
Glucagon-like peptide-1 agonists and general anesthesia: Perioperative considerations and the utility of gastric ultrasound.
Cureus
2024
;
16
:
e58042